Palavras-chave
Embolia pulmonar
Estratificação de risco
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Analisar, à luz da literatura científica, a associação entre o uso de contraceptivos hormonais combinados e o risco de desenvolvimento de tromboembolismo venoso em mulheres, contribuindo para uma compreensão crítica e atualizada dessa relação sob a perspectiva clínica e epidemiológica. Métodos: Trata-se de uma revisão integrativa da literatura, orientada pelas recomendações do checklist PRISMA 2020, com busca nas bases PubMed/MEDLINE, SciELO e Biblioteca Virtual em Saúde. Foram incluídos estudos publicados entre 2021 e 2026, em português ou inglês, disponíveis na íntegra e relacionados ao tema. Resultados: A busca identificou 312 registros, dos quais oito estudos compuseram a síntese final. Os achados evidenciaram aumento do risco tromboembólico, especialmente em formulações contendo etinilestradiol, enquanto contraceptivos com estrogênios naturais apresentaram perfil mais favorável em parte dos estudos. Observou-se também que idade, obesidade, tabagismo, trombofilias e predisposição genética influenciam esse risco. Considerações finais: Há associação entre contraceptivos hormonais combinados e tromboembolismo venoso, embora essa relação varie conforme a formulação e o perfil clínico da usuária, reforçando a necessidade de prescrição individualizada.
Referências
ANDERSON DJ, JOHNSTON DS. A brief history and future prospects of contraception. Science, 2023; 380(6641): 154-158.
AZIZ D, et al. Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: data from REVERSE cohort study. Journal of Thrombosis and Haemostasis, 2021; 19(6): 1526-1532.
BABANIYI GG, et al. Reproductive endocrinology drug development: hormones, metabolism, and fertility in female reproductive health. In: Perspectives of Quorum Quenching in New Drug Development. CRC Press, 2024; 187-206.
BAUERFEIND A, et al. Venous thromboembolic risk of estradiol valerate-dienogest compared with ethinyl estradiol-levonorgestrel combined oral contraceptives. Obstetrics & Gynecology, 2024; 143(3): 431-434.
DOUXFILS J, et al. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. Frontiers in Endocrinology, 2024; 15: 1428597.
HASSER EK, et al. Genome-wide investigation of exogenous female hormones, genetic variation, and venous thromboembolism risk. Journal of Thrombosis and Haemostasis, 2024; 22(8): 2261-2269.
HEIKINHEIMO O, et al. Systemic hormonal contraception and risk of venous thromboembolism. Acta Obstetricia et Gynecologica Scandinavica, 2022; 101(8): 846-855.
INMAN WHW et al. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Irish Medical Journal, 1970; 2: 209-209.
JORDAN WM, ANAND JK. Pulmonary embolism. The Lancet, 1961; 278: 1146-1147.
KHIZROEVA J, et al. Combined oral contraceptives and the risk of thrombosis. International Journal of Molecular Sciences, 2025; 26(22): 11010-11010.
KUIJPERS MJ, et al. Molecular mechanisms of hemostasis, thrombosis and thrombo-inflammation. International Journal of Molecular Sciences, 2022; 23(10): 5825-5825.
LAVASSEUR C, et al. Hormonal therapies and venous thrombosis: considerations for prevention and management. Research and Practice in Thrombosis and Haemostasis, 2022; 6(6): e12763-e12763.
LO FARO V, et al. The risk of venous thromboembolism in oral contraceptive users: the role of genetic factors—a prospective cohort study of 240,000 women in the UK Biobank. American Journal of Obstetrics and Gynecology, 2024; 230(3): 360.e1-360.e13.
LU Y et al. Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system. Frontiers in Pharmacology, 2024; 15: 1486422.
MACKMAN N, et al. Therapeutic strategies for thrombosis: new targets and approaches. Nature Reviews Drug Discovery, 2020; 19(5): 333-352.
MORIMONT L, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Frontiers in Endocrinology, 2021; 12: 769187.
PASTORI D, et al. A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. International Journal of Molecular Sciences, 2023; 24(4): 3169-3169.
REED S, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5 mg) and 17β-oestradiol (1.5 mg) (PRO-E2 study): risk of venous and arterial thromboembolism. The European Journal of Contraception & Reproductive Health Care, 2021; 26(6): 439-446.
SCHINK T, et al. Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data. BJOG: An International Journal of Obstetrics and Gynaecology, 2022; 129(13): 2107-2116.
VATANDOOST J, et al. Testosterone replacement has a beneficial effect on the hemostatic system by altered gene expression of coagulation factors. Steroids, 2024; 212: 109525.
VON STOCKUM S, et al. NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study. Gynecological Endocrinology, 2023; 39(1): 2166032.
WIEGERS HMG, et al. Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2022; 20(5): 1158-1165.